News|Articles|November 16, 2026

Cenobamate sNDA Seeks FDA Approval for Generalized Seizures

Author(s)Marco Meglio
Listen
0:00 / 0:00

Key Takeaways

  • FDA sNDA seeks a PGTC indication for cenobamate, alongside separate submissions for pediatric focal-onset expansion and an oral suspension to address dysphagia and administration barriers.
  • Phase 3 YKP3089C025 randomized 169 patients (including 34 adolescents) to cenobamate 200 mg/day versus placebo with 10-week titration and 12-week maintenance after a 12-week baseline.
SHOW MORE

A new FDA filing seeks to expand cenobamate's epilepsy indication to primary generalized tonic-clonic seizures, based on positive phase 3 trial data.

SK Biopharmaceuticals announced the submission of a supplemental new drug application (sNDA) to the FDA, seeking approval of cenobamate (Xcopri) for primary generalized tonic-clonic (PGTC) seizures, a new indication beyond its current approval for focal-onset seizures in adults. The filing is backed by positive results from a phase 3 trial of adjunctive cenobamate in patients with PGTC seizures.1,2

The PGTC filing is one of 3 regulatory submissions the company disclosed together on November 4, 2026: a separate sNDA submitted in October 2026 seeking to expand the existing focal-onset seizure indication to pediatric patients, and a new drug application submitted in March 2026 for an oral suspension formulation for patients who have difficulty swallowing tablets. “This submission represents an important step in our continued investment in cenobamate and our efforts to reach more people living with epilepsy,” Donghoon Lee, CEO of SK Biopharmaceuticals, said in a statement.1

Data from the PGTC trial (YKP3089C025; NCT03678753) was presented in full at the 2026 American Academy of Neurology Annual Meeting, held April 18-22 in Chicago. It randomized 169 patients, including 34 adolescents, 1:1 to adjunctive cenobamate 200 mg/day or placebo, following a titration schedule outlined when the trial began enrolling: a 10-week up-titration to the 200 mg target dose, followed by a 12-week maintenance period. Eligible patients had idiopathic generalized epilepsy with at least 3 PGTC seizures during a 12-week baseline period.2

On the trial's primary measure, cenobamate produced a median 71.9% reduction in PGTC seizure frequency during the double-blind period, compared with 39.6% with placebo (P =.003). Among the 168 patients analyzed, cenobamate also produced a 71.1% responder rate (at least a 50% seizure reduction) during maintenance, compared with 51.3% with placebo (P =.01), and 43.4% of cenobamate-treated patients were seizure-free during maintenance, compared with 20.5% on placebo (P =.002).

READ MORE: On Beyond Seizures: Unmet Needs in Pediatric Epilepsy Clinics

Treatment-emergent adverse events occurred in 60.0% of cenobamate-treated patients versus 53.0% on placebo, most commonly somnolence (16.5%) and fatigue (10.6%). No treatment-related serious adverse events, deaths, or cases of drug reaction with eosinophilia and systemic symptoms (DRESS) were reported.2

A decade-long regulatory build-out

Cenobamate was originally approved by the FDA in November 2019 for focal-onset (partial-onset) seizures in adults, based on 2 placebo-controlled trials in 655 patients that showed median seizure-frequency reductions of up to 55.6% with 200 mg/day, versus roughly 21.5% to 24.3% with placebo.3 That approval followed a titration redesign after earlier dosing led to cases of DRESS, including 1 fatality; the slower titration schedule used in the approved label, and in the PGTC trial above, reported no DRESS cases among more than 1300 patients studied.

Commercial launch was delayed into the second quarter of 2020 pending a Drug Enforcement Administration review, which designated cenobamate a Schedule V controlled substance, the lowest-risk tier for scheduled drugs. In 2024, the FDA approved 2 additional administration routes, allowing a crushed tablet to be suspended in water and taken orally or through a nasogastric tube, an option aimed at patients who have difficulty swallowing.

Cenobamate carries no boxed warning; its current label lists warnings for QT interval shortening, DRESS, suicidal behavior and ideation, and hepatic failure, the last added in January 2024.4 The drug is approved in more than 45 countries and is marketed in the European Union and UK by Angelini Pharma under the brand name Ontozry.1

If the PGTC indication is approved, cenobamate would join a small group of antiseizure medications labeled for both focal and generalized seizure types, a distinction few drugs carry. “We are building on the foundation established with cenobamate in focal-onset seizures in adults by evaluating its potential in additional seizure types, age groups and formulations,” Lee said.1 The FDA has not stated a target action date for any of the 3 pending submissions.

REFERENCES
1. SK Biopharmaceuticals submits supplemental New Drug Application to U.S. FDA for cenobamate. News release. SK Biopharmaceuticals. Published November 4, 2026. Accessed November 13, 2026. https://www.prnewswire.com/news-releases/sk-biopharmaceuticals-submits-supplemental-new-drug-application-to-us-fda-for-cenobamate-302929394.html
2. Shih E, Bar M, Farkas M, Klein P, Vossler D, Misra S. Efficacy and safety of adjunctive cenobamate for the treatment of primary generalized tonic-clonic seizures in adults and adolescents. Presented at: 2026 American Academy of Neurology Annual Meeting; April 18-22, 2026; Chicago, IL.
3. Drug trials snapshot: Xcopri. FDA. Published 2019. Accessed November 13, 2026. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xcopri
4. Xcopri (cenobamate) tablets, for oral use, CV. Prescribing information. SK Life Science, Inc. Revised 2025. Accessed November 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212839s013lbl.pdf

Related to this article